US-based biopharmaceutical company Accent Therapeutics has dosed the first subject in an open-label Phase I/II trial of ATX-295, an oral kinesin family member 18A (KIF18A) inhibitor. The dose ...

For Accent's second lead program, preclinical data included in the company's oral presentation demonstrates sensitivity to KIF18A inhibition across several solid tumor indications with high ...